Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lung Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
80 drugs · 288 active trials
21 drugs · 611 active trials
51 drugs · 1,372 active trials
Outside the funnel: Phase not stated 2 · Withdrawn 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 9 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Fludarabine | Phase 2 | Phase 2 | 13 | 8 | 0 | 28 | 0 | — | — | 1999-09 |
| Aldesleukin | Phase 2 | Phase 2 | 8 | 7 | 0 | 21 | 0 | — | — | 1996-01 |
| Fulvestrant | Phase 2 | Phase 2 | 7 | 5 | 0 | 15 | 0 | — | — | Oct 28, 2004 |
| Trastuzumab | Phase 2 | Phase 2 | 5 | 2 | 0 | 19 | 0 | — | — | 1999-05 |
| Berzosertib | Phase 2 | Phase 2 | 5 | 0 | 0 | 7 | 0 | — | — | Jul 22, 2016 |
| Pyrotinib | Phase 2 | Phase 2 | 4 | 2 | 0 | 8 | 0 | — | — | 2015-01 |
| Lifileucel | Phase 2 | Phase 2 | 4 | 4 | 0 | 6 | 0 | — | — | Feb 28, 2018 |
| Ruxolitinib | Phase 2 | Phase 2 | 4 | 2 | 0 | 6 | 0 | — | — | Feb 11, 2014 |
| Sapanisertib | Phase 2 | Phase 2 | 3 | 0 | 0 | 8 | 0 | — | — | Aug 17, 2015 |
| Befotertinib | Phase 2 | Phase 2 | 3 | 2 | 0 | 6 | 0 | — | — | Jan 3, 2018 |
| Ribociclib | Phase 2 | Phase 2 | 3 | 2 | 0 | 6 | 0 | — | — | May 14, 2015 |
| Platinum Doublet | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Jul 23, 2019 |
| Panitumumab | Phase 2 | Phase 2 | 2 | 2 | 0 | 13 | 0 | — | — | 2000-04 |
| Alisertib | Phase 2 | Phase 2 | 2 | 2 | 0 | 7 | 0 | — | — | 2010-02 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 2 | 1 | 0 | 6 | 0 | — | — | 2007-07 |
| Prednisone | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 2009-03 |
| Guadecitabine | Phase 2 | Phase 2 | 2 | 0 | 0 | 4 | 0 | — | — | Jan 26, 2017 |
| Regorafenib | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Sep 28, 2016 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | 1996-02 |
| Carboplatin/Pemetrexed Regimen | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Oct 12, 2017 |
| Disitamab Vedotin | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Sep 26, 2018 |
| Gilteritinib | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Sep 8, 2015 |
| Obinutuzumab | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Aug 6, 2021 |
| Larotrectinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Zanidatamab | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Jan 14, 2025 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 11 | 0 | — | — | 2006-06 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | 2014-03 |
| Pemigatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | Feb 27, 2015 |
| Selinexor | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | 2015-05 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | Dec 15, 2014 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2003-07 |
| Venetoclax | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Apr 14, 2015 |
| Vistusertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | May 13, 2015 |
| Carfilzomib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2007-09 |
| Enzalutamide | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | Jun 17, 2016 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Tisotumab Vedotin | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Nov 30, 2013 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| FOLFIRI Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2013-12 |
| PD1 Inhibitor | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Apr 26, 2021 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Jul 16, 2009 |
| Anastrozole | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2010-09 |
| Anti-PD1 Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jul 6, 2023 |
| Barasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Dec 1, 2017 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | May 13, 2015 |
| Daratumumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Dec 23, 2016 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Lomustine | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2005-07 |
| Methotrexate | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 14, 2018 |
| Mocetinostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 7, 2016 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.